Q4 EPS Estimates for Journey Medical Raised by HC Wainwright

Journey Medical Corporation (NASDAQ:DERM) – Equities researchers at HC Wainwright raised their Q4 2026 earnings per share estimates for Journey Medical in a report released on Thursday, April 23rd. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $0.22 for the quarter, up from their prior estimate of $0.17. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Journey Medical’s current full-year earnings is $0.19 per share.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Journey Medical had a negative return on equity of 46.40% and a negative net margin of 18.48%.The company had revenue of $16.08 million for the quarter, compared to analyst estimates of $18.86 million.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research report on Monday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Journey Medical presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Journey Medical Price Performance

Shares of DERM opened at $5.13 on Friday. The company has a current ratio of 1.79, a quick ratio of 1.53 and a debt-to-equity ratio of 0.79. The firm’s fifty day simple moving average is $6.64 and its 200-day simple moving average is $7.50. The firm has a market capitalization of $140.20 million, a price-to-earnings ratio of -10.91 and a beta of 1.03. Journey Medical has a twelve month low of $4.31 and a twelve month high of $9.56.

Institutional Investors Weigh In On Journey Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors LP boosted its position in Journey Medical by 62.1% during the first quarter. Wasatch Advisors LP now owns 2,133,370 shares of the company’s stock worth $10,006,000 after purchasing an additional 817,095 shares in the last quarter. Opaleye Management Inc. increased its position in shares of Journey Medical by 0.4% in the fourth quarter. Opaleye Management Inc. now owns 975,000 shares of the company’s stock valued at $7,517,000 after buying an additional 3,936 shares in the last quarter. J. Goldman & Co LP acquired a new position in shares of Journey Medical during the 4th quarter worth $6,155,000. Vanguard Group Inc. grew its stake in Journey Medical by 8.9% in the 3rd quarter. Vanguard Group Inc. now owns 615,229 shares of the company’s stock valued at $4,380,000 after acquiring an additional 50,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in Journey Medical in the 4th quarter valued at about $3,530,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.